251 related articles for article (PubMed ID: 27232892)
1. Avanafil - a further step to tailoring patient needs and expectations.
Boeri L; Capogrosso P; Ventimiglia E; Serino A; La Croce G; Russo A; Damiano R; Montorsi F; Salonia A
Expert Rev Clin Pharmacol; 2016 Sep; 9(9):1171-81. PubMed ID: 27232892
[TBL] [Abstract][Full Text] [Related]
2. The safety and efficacy of Avanafil, a new 2(nd) generation PDE5i: comprehensive review and meta-analysis.
Corona G; Rastrelli G; Burri A; Jannini EA; Maggi M
Expert Opin Drug Saf; 2016; 15(2):237-47. PubMed ID: 26646748
[TBL] [Abstract][Full Text] [Related]
3. Avanafil for the treatment of erectile dysfunction.
Zurawin JL; Stewart CA; Anaissie JE; Yafi FA; Hellstrom WJ
Expert Rev Clin Pharmacol; 2016 Sep; 9(9):1163-70. PubMed ID: 27416913
[TBL] [Abstract][Full Text] [Related]
4. Avanafil for the treatment of erectile dysfunction. An updated review.
Egui-Rojo MA; Moncada-Iribarren I; Carballido-Rodríguez J; Martínez-Salamanca JI
Arch Esp Urol; 2014 Dec; 67(10):839-47. PubMed ID: 25582903
[TBL] [Abstract][Full Text] [Related]
5. Selectivity of avanafil, a PDE5 inhibitor for the treatment of erectile dysfunction: implications for clinical safety and improved tolerability.
Wang R; Burnett AL; Heller WH; Omori K; Kotera J; Kikkawa K; Yee S; Day WW; DiDonato K; Peterson CA
J Sex Med; 2012 Aug; 9(8):2122-9. PubMed ID: 22759639
[TBL] [Abstract][Full Text] [Related]
6. Avanafil for erectile dysfunction.
Kyle JA; Brown DA; Hill JK
Ann Pharmacother; 2013 Oct; 47(10):1312-20. PubMed ID: 24259695
[TBL] [Abstract][Full Text] [Related]
7. Avanafil, a new rapid-onset phosphodiesterase 5 inhibitor for the treatment of erectile dysfunction.
Limin M; Johnsen N; Hellstrom WJ
Expert Opin Investig Drugs; 2010 Nov; 19(11):1427-37. PubMed ID: 20939743
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of avanafil for treating erectile dysfunction: results of a multicentre, randomized, double-blind, placebo-controlled trial.
Zhao C; Kim SW; Yang DY; Kim JJ; Park NC; Lee SW; Paick JS; Ahn TY; Moon KH; Chung WS; Min KS; Suh JK; Hyun JS; Park K; Park JK
BJU Int; 2012 Dec; 110(11):1801-6. PubMed ID: 22448738
[TBL] [Abstract][Full Text] [Related]
9. Avanafil for male erectile dysfunction: a systematic review and meta-analysis.
Cui YS; Li N; Zong HT; Yan HL; Zhang Y
Asian J Androl; 2014; 16(3):472-7. PubMed ID: 24589460
[TBL] [Abstract][Full Text] [Related]
10. Avanafil for the treatment of erectile dysfunction.
Segal R; Burnett AL
Drugs Today (Barc); 2012 Jan; 48(1):7-15. PubMed ID: 22384456
[TBL] [Abstract][Full Text] [Related]
11. A survey on the experience of 136 Italian urologists in the treatment of erectile dysfunction with PDE5 inhibitors and recommendations for the use of Avanafil in the clinical practice.
Mirone V; Fusco F; Parazzini F; Zucchi A
Arch Ital Urol Androl; 2016 Jul; 88(2):128-32. PubMed ID: 27377089
[TBL] [Abstract][Full Text] [Related]
12. A randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of avanafil in subjects with erectile dysfunction.
Goldstein I; McCullough AR; Jones LA; Hellstrom WJ; Bowden CH; Didonato K; Trask B; Day WW
J Sex Med; 2012 Apr; 9(4):1122-33. PubMed ID: 22248153
[TBL] [Abstract][Full Text] [Related]
13. Future prospects in the treatment of erectile dysfunction: focus on avanafil.
Alwaal A; Al-Mannie R; Carrier S
Drug Des Devel Ther; 2011; 5():435-43. PubMed ID: 22087063
[TBL] [Abstract][Full Text] [Related]
14. Avanafil (Stendra)--another PDE5 inhibitor for erectile dysfunction.
Med Lett Drugs Ther; 2014 May; 56(1442):37-8. PubMed ID: 24818838
[No Abstract] [Full Text] [Related]
15. Avanafil for treatment of erectile dysfunction: review of its potential.
Burke RM; Evans JD
Vasc Health Risk Manag; 2012; 8():517-23. PubMed ID: 22973106
[TBL] [Abstract][Full Text] [Related]
16. Update on the Safety of Phosphodiesterase Type 5 Inhibitors for the Treatment of Erectile Dysfunction.
Yafi FA; Sharlip ID; Becher EF
Sex Med Rev; 2018 Apr; 6(2):242-252. PubMed ID: 28923561
[TBL] [Abstract][Full Text] [Related]
17. The safety of phosphodiesterase type 5 inhibitors for erectile dysfunction.
Ventimiglia E; Capogrosso P; Montorsi F; Salonia A
Expert Opin Drug Saf; 2016; 15(2):141-52. PubMed ID: 26752541
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Avanafil 15 Minutes after Dosing in Men with Erectile Dysfunction: A Randomized, Double-Blind, Placebo Controlled Study.
Hellstrom WJ; Kaminetsky J; Belkoff LH; Goldstein I; Tursi JP; Uy J; Peterson CA; Bowden CH; Day WW
J Urol; 2015 Aug; 194(2):485-92. PubMed ID: 25591992
[TBL] [Abstract][Full Text] [Related]
19. Erectile function recovery in men treated with phosphodiesterase type 5 inhibitor administration after bilateral nerve-sparing radical prostatectomy: a systematic review of placebo-controlled randomized trials with trial sequential analysis.
Limoncin E; Gravina GL; Corona G; Maggi M; Ciocca G; Lenzi A; Jannini EA
Andrology; 2017 Sep; 5(5):863-872. PubMed ID: 28787547
[TBL] [Abstract][Full Text] [Related]
20. Phosphodiesterase 5 inhibitors for the treatment of erectile dysfunction: a trade-off network meta-analysis.
Chen L; Staubli SE; Schneider MP; Kessels AG; Ivic S; Bachmann LM; Kessler TM
Eur Urol; 2015 Oct; 68(4):674-80. PubMed ID: 25817916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
